Acorda's $525m Civitas buy: Sign of Parkinson's deal surge?

Civitas Therapeutics has a lot to offer its buyer Acorda Therapeutics, including global diversification and an inhaled drug platform technology. The private company's $525m acquisition adds to a growing list of recent transactions in the Parkinson's disease field.